• Stryker Corporation (NYSE: SYK) announced that its Q Guidance System with Cranial Guidance Software received FDA510(k) clearance.

• The Q Guidance System is an image-based planning and intraoperative guidance system designed to support cranial surgeries.

• Recently launched in September 2022, the Q Guidance System for spinal applications is currently available on the market.

• It tracks navigated instruments and displays the position and orientation of the instruments in patient images.

• Related: Stryker Expects Good Momentum In 2023 Despite Some Volatility.

• The Cranial Guidance Software includes automatic, algorithmic processing and comprehensive guidance data that aim to elevate confidence and surgical ability.

• The Cranial Guidance Software is powered by Stryker's Q Guidance System and can be used with various instruments and accessories for navigated cranial procedures.

• New for brain biopsies, the software provides a dedicated workflow to support the accurate alignment of the Precision Targeting System with a pre-operatively planned approach.

• Stryker is also leveraging plug-in EM tracking technology that can be used with adults and pediatric patients to place shunt catheters, which can be visualized with an EM Stylet.

• Price Action: SYK shares are down 0.55% at $261.77 on the last check Friday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Stryker's Q Guidance System Scores FDA Clearance For Cranial Applications originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.